Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2013. The report details a specific share repurchase transaction executed on June 13, 2013, authorized by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 448,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,688.5 pence per share; lowest price paid was 1,659.5 pence per share.
- Treasury Holdings (Settled): 509,044,512 shares, representing 9.38% of total issued share capital.
- Treasury Holdings (Including Unsettled): 510,741,512 shares, representing 10.38% of total voting rights.
- Shares in Issue (Excluding Treasury): 4,920,585,477 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 448,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.38% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure under the Financial Conduct Authority's Disclosure and Transparency Rules regarding share ownership thresholds.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (509,044,512 settled) against the company's latest capitalization table.
- Confirm the calculation of voting rights (10.38% including unsettled shares) for disclosure threshold assessments.
- Check the price paid per share (1,659.5 to 1,688.5 pence) against market trading data for June 13, 2013.
- Note that this filing does not contain operational or financial performance data for the period.